Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The data, consistent with a prior Phase 2 trial in China, ...